Pro 2014-001 (Announcement of Resolution of 14th Session of 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2014-001
浙江尖峰集团股份有限公司
八届十四次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
二〇一四年三月三十一日,浙江尖峰集团股份有限公司以传真、电子邮件及专人送达的方式发出了召开第八届董事会第十四次会议的通知。二〇一四年四月十一日,会议如期在浙江金华尖峰大厦会议室召开。会议由蒋晓萌董事长主持,独立董事邓明然因出差委托独立董事刘家健出席会议,其余八名董事亲自参加了会议;公司监事和高级管理人员列席了会议,符合《公司法》和公司《章程》的有关规定,所做决议合法有效。会议通过了如下决议:
一、通过了2013年度总经理业务报告
经审议,董事会一致通过了该报告,认为2013年公司经营班子的工作是卓有成效的,较好完成了各项经营任务,取得了良好的经营业绩;董事会批准了报告中提出的2014年各项工作安排。
表决结果:同意9票、反对0票、弃权0票。
二、通过了2013年度财务决算报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
三、通过了2013年度利润分配预案
经天健会计师事务所审计,2013年度公司合并报表归属于母公司股东的净利润为201,569,075.92元;母公司会计报表净利润40,440,909.88元。按母公司的本期净利润40,440,909.88元为基数,提取10%法定公积金4,044,090.99元,加年初未分配利润291,235,211.25元,减去2012年度现金分红51,612,574.2元,本年度可供分配利润为276,019,455.94 元。
公司2013年度拟进行现金分配,以2013年末股本344,083,828股为基数,每10股派发现金红利1.8元(含税),向股权登记日登记在册的全体股东派发现金股利总额为61,935,089.04 元(含税)。2013年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
四、通过了聘请2014年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所为公司2014年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
该议案将提交股东大会审议。
五、通过了关于计提资产减值准备和核销资产的议案
董事会审议并通过了该议案,同意计提以下资产减值准备和核销以下已全额计提减值准备的资产:
(一)计提资产减值准备的情况:
1、子公司浙江尖峰药业有限公司秋滨制药厂因实施GMP改造,计提设备等固定资产减值准备218.65万元。
2、子公司浙江尖峰通信电缆有限公司部分车间因转型拆除,计提固定资产减值准备51.84万元和存货跌价准备21.68万元。
3、子公司浙江尖峰国际贸易有限公司因开展代理进口电解铜业务,产生应收帐款纠纷,并已向法院提起诉讼并申请了资产保全。经测算,对该笔应收帐款计提坏帐准备564.82万元。
4、经测试,子公司浙江尖峰通信电缆有限公司和浙江尖峰国际贸易公司的商誉发生了减值,共需计提商誉减值准备73.10万元,其中:尖峰电缆47.15万元,尖峰国贸25.95万元。
以上计提资产减值准备金额合计930.09万元。
(二)资产核销的情况:
公司应收参股子公司博信电池(上海)有限公司的暂借款600万元(2008年以前发生),因该公司已停止经营,且该借款期限也已超过五年,确定无法收回,予以核销。该借款已于以前年度全额计提坏账准备,本次核销不影响当期损益。
表决结果:同意9票、反对0票、弃权0票。
六、通过了2013年年度报告及其摘要
表决结果:同意9票、反对0票、弃权0票。
该报告需提交股东大会审议。
2013年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
七、通过了关于为控股子公司提供担保的议案
董事会一致通过了该议案,同意为控股子公司提供以下担保事宜。
1、对控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
10000 |
|
浙江尖峰药业有限公司 |
20000 |
|
金华市医药公司 |
10000 |
|
浙江尖峰国际贸易有限公司 |
5000 |
|
云南尖峰水泥有限公司 |
5000 |
|
合计 |
50000 |
2、同意为浙江尖峰国际贸易有限公司提供担保函,为浙江尖峰国际贸易有限公司的客户在该公司存放的货物提供相应的担保。
在以上额度内的担保授权董事长分次执行。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2014-003)。
八、通过了与浙江凯恩特种材料股份有限公司互相担保的议案
董事会审议并通过了该议案,同意与浙江凯恩特种材料股份有限公司进行额度为5000万元、期限为一年的等额互保。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《与浙江凯恩特种材料股份有限公司互相担保的公告》(临2014-004)。
九、通过了公司《章程》修订议案
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《关于修订章程的公告》(临2014-007)。
十、通过了日常关联交易议案
董事会审议并通过了该议案。关联董事蒋晓萌先生、杜自弘先生回避了该项议案的表决。
表决结果:同意7票、反对0票、弃权0票。
详见《日常关联交易公告》(临2014-005)。
十一、通过了聘任证券事务代表的议案
董事会审议并通过了该议案,决定聘任周恒斌先生为本公司的证券事务代表。周恒斌先生的简历附后。
表决结果:同意9票、反对0票、弃权0票。
十二、通过了2013年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2013年度内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
十三、通过了2013年独立董事述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
该报告需提交股东大会审议。
2013年独立董事述职报告详见上海证券交易所网站(www.sse.com.cn)。
十四、通过了2013年度审计委员会履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
2013年度审计委员会履职报告详见上海证券交易所网站(www.sse.com.cn)。
十五、通过了关于召开2013年度股东大会的议案
董事会决定于2014年6月6日在浙江省金华市婺江东路88号尖峰大厦召开2013年度股东大会。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2013年度股东大会的通知》(临2014-006)。
十六、通过了关于对子公司增加注册资本的议案
董事会审议并通过了该议案。同意公司用自有资金1500万元对子公司浙江尖峰健康科技有限公司进行增资,增资完成后该子公司注册资本增加到3000万元,本公司持有其100%股权。
表决结果:同意9票、反对0票、弃权0票
十七、通过了关于注销浙江金华中能物产有限公司的议案
表决结果:同意9票、反对0票、弃权0票。
详见《关于注销子公司的公告》(临2014-008)。
十八、通过了2013年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一四年四月十五日
简历:
周恒斌,男,1986年10月出生,大学本科。2010年1月加入本公司,曾在浙江尖峰药业有限公司工作,2013年4月至今在本公司董事会办公室工作。已参加上海证券交易所举办的相关培训,并取得了上海证券交易所颁发的董事会秘书资格证书。
电话:0579-82324699
传真:0579-82324699
邮箱:jf@jianfeng.com.cn
地址:浙江省金华市婺江东路88号
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31